Q-Line Biotech AGM votes and auditors

NSE: QLINEHealthcare Equipment & Supplies

Q-Line Biotech Limited · Face value ₹10 · Listed May 2026 · Issue price ₹343

₹512.75₹26.30 (4.88%)

Share price at the NSE close on 30 Oct 2026. Previous close ₹539.05.

30 Oct: open ₹538.00, high ₹538.00, low ₹509.55

Range of traded prices from listing on 29 May 2026 to 30 Oct 2026

₹431.00Low, 29 May 2026₹735.00High, 15 Sep 2026

Market cap: ₹1,196 Cr
P/E: 21.47
P/B: Shares changed
Dividend yield: Nonesince listing in May 2026
ROE: 22.6%
Debt to equity: 0.92
Volume, NSE: 66,80059.3% delivered

Q-Line Biotech board of directors

At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

Statutory auditor

Named in the results for the quarter to Mar 2026.

R K Jagetiya & Co.Peer-review certificate valid to Jun 2027

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Q-Line Biotech AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Q-Line Biotech share news and announcements

Annual general meeting, 30 Sep 2026

2,928 shareholders on the register on 23 Sep 2026; present: 5 promoters and 13 others; votes counted by SUKHMENDRA KUMAR / MMA & PARTNERS.The company's voting result

1 (A). ADOPTION OF STANDALONE ANNUAL AUDITED FINANCIAL STATEMENTS (B). ADOPTION OF CONSOLIDATED ANNUAL AUDITED FINANCIAL STATEMENTS
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.01% · promoters 99.47% · institutions 53.83% · other public 8.82%
TO APPOINT A DIRECTOR IN PLACE OF MR. AJAY KUMAR MAHANTY, WHO RETIRES BY ROTATION AND, BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 74.01% · promoters 99.47% · institutions 53.83% · other public 8.82%
TO APPOINT A DIRECTOR IN PLACE OF MR. KULDEEP CHOWDHARY, WHO RETIRES BY ROTATION AND, BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT
Ordinary
99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.25%
Turnout: all 74.01% · promoters 99.47% · institutions 53.83% · other public 8.82%
TO RATIFY THE REMUNERATION OF THE COST AUDITOR DOE THE FINANCIAL YEAR 2026-27
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.16%
Turnout: all 74.01% · promoters 99.47% · institutions 53.83% · other public 8.82%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

How mutual funds voted

Fund houses must disclose how they vote at every meeting of a company they hold.

Mutual fund votes, meeting of 30 Sep 2026, 1 fund house

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

1 (A). ADOPTION OF STANDALONE ANNUAL AUDITED FINANCIAL STATEMENTS (B). ADOPTION OF CONSOLIDATED ANNUAL AUDITED FINANCIAL STATEMENTS
1 for0 against
TO APPOINT A DIRECTOR IN PLACE OF MR. AJAY KUMAR MAHANTY, WHO RETIRES BY ROTATION AND, BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT
1 for0 against
TO APPOINT A DIRECTOR IN PLACE OF MR. KULDEEP CHOWDHARY, WHO RETIRES BY ROTATION AND, BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT
1 for0 against

1 proposal not matched to one resolution

Ratification of remuneration of Rs. 1,20,000/- plus applicable taxes and reimbursement of reasonable out-of-pocket expenses, payable to M/s P S P and Associates, Cost Accountants (Firm Registration No. 005591), appointed by the Board of Directors as the Cost Auditor of the Company for the financial year 2026-27.MoreLess
1 for0 against

Each fund house counted once, from its own disclosure; the reasons are its own words.

Dealings with its subsidiaries, promoters, directors and their firms, reported every half-year.Promoters and their stake

Half-year to Mar 2026: ₹266 Cr43 dealings

Between	Dealing
Q-LINE BIOTECH LIMITED and POCT ServicesFirm in Which Director is partner	Sale of goods or services	500.00	225.88	0.00	0.00
Q-LINE BIOTECH LIMITED and Q-Line Innovation Private LimitedSubsidiary (w.e.f 07th March, 2025)	Any other transactionloan repaid during the year	10.00	9.92	0.00	0.00
Q-LINE BIOTECH LIMITED and Q-Line Innovation Private LimitedSubsidiary (w.e.f 07th March, 2025)	Loan	10.00	9.80	0.00	0.00
Q-LINE BIOTECH LIMITED and Heidelco Medicore Private LimitedCommon Directorship (Substantial Interest)	Sale of goods or services	7.00	5.11	0.00	0.00
Q-LINE BIOTECH LIMITED and Heidelco Medicore Private LimitedCommon Directorship (Substantial Interest)	Purchase of goods or services	7.00	4.78	0.00	0.00
Q-LINE BIOTECH LIMITED and Ayush GargPromoter and Whole- Time Director (w.e.f. 25th July, 2025)	Remuneration	1.50	1.61	0.05	0.05
Q-LINE BIOTECH LIMITED and Saurabh GargPromoter, Managing Director and Chairman	Remuneration	1.50	1.34	0.00	0.14
Q-LINE BIOTECH LIMITED and Ajay Kumar MahantyPromoter and Whole- Time Director	Remuneration	1.50	1.00	0.05	0.06
Q-LINE BIOTECH LIMITED and Q-Line Innovation Private LimitedSubsidiary (w.e.f 07th March, 2025)	Sale of goods or services	1.00	0.97	0.00	0.00
Q-LINE BIOTECH LIMITED and ASG Buildtech Pvt LimitedCommon Directorship (Substantial Interest)	Purchase of fixed assets	1.00	0.94	0.00	0.00
Q-LINE BIOTECH LIMITED and POCT ServicesFirm in Which Director is partner	Purchase of goods or services	5.00	0.75	0.00	0.00
Q-LINE BIOTECH LIMITED and Kuldeep ChowdhryWhole- Time Director	Remuneration	1.50	0.73	0.03	0.05
Q-LINE BIOTECH LIMITED and Amit AgrawalRelative of KMP	Remuneration	1.50	0.72	0.02	0.05
Q-LINE BIOTECH LIMITED and Meenal GuptaCFO (w.e.f 25th July, 2025)	Remuneration	1.50	0.48	0.03	0.03
Q-LINE BIOTECH LIMITED and Prabhakara Subraya YethadkaWhole- Time Director (w.e.f 08th May, 2025)	Remuneration	1.50	0.27	0.00	0.02
Q-LINE BIOTECH LIMITED and Amita GargPromoters and Non-Executive Director	Any other transactionrent expense	0.30	0.24	0.00	0.00
Q-LINE BIOTECH LIMITED and Abhay AgarwalPromoters & Non-Executive Director	Loan	0.50	0.19	0.19	0.00
Q-LINE BIOTECH LIMITED and POCT Quality & Skill Development FoundationCommon Directorship (Substantial Interest)	Any other transactionPayment towards CSR Obligation	0.50	0.15	0.00	0.00
Q-LINE BIOTECH LIMITED and Akhand Pratap SinghCompany Secretary (w.e.f 25th July, 2025)	Remuneration	1.50	0.13	₹83,000	0.01
Q-LINE BIOTECH LIMITED and Q-Line Innovation Private LimitedSubsidiary (w.e.f 07th March, 2025)	Interest paid	0.50	0.12	0.00	0.00
Q-LINE BIOTECH LIMITED and Kuldeep ChowdhryWhole- Time Director	Any other transactionReimbursement of expenses	0.30	0.07	₹13,000	−0.02
Q-LINE BIOTECH LIMITED and POCT ServicesFirm in Which Director is partner	Any other transactionRent Income of the company	0.20	0.06	0.00	0.00
Q-LINE BIOTECH LIMITED and Q-Line Innovation Private LimitedSubsidiary (w.e.f 07th March, 2025)	Purchase of goods or services	1.00	0.05	0.00	0.00
Q-LINE BIOTECH LIMITED and Ajay Kumar MahantyPromoter and Whole- Time Director	Any other transactionReimbursement of expenses	0.30	0.04	0.00	0.02
Q-LINE BIOTECH LIMITED and Amit AgarwalRelative of KMP	Loan	0.50	0.04	0.00	0.00

The 25 largest of 43 dealings in the half-year to Mar 2026, ₹ crore.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

Received
Resolved

Open at the quarter's end

None open at any quarter's end.

The filing has a part on fines and penalties: No
The filing has a part on tax disputes: No

The company's own answers in its filing.

How money raised was used

The company's results filing for the quarter to Mar 2026 says no statement of how money raised was used applies to it.